You are viewing the site in preview mode

Skip to content

Advertisement

  • Research article
  • Open Access
  • Open Peer Review

Oseltamivir in pregnancy and birth outcomes

BMC Infectious Diseases201818:519

https://doi.org/10.1186/s12879-018-3423-z

  • Received: 5 October 2017
  • Accepted: 27 September 2018
  • Published:
Open Peer Review reports

Abstract

Background

Prenatal exposure to influenza or fever is associated with risk of congenital malformations. Oseltamivir is used to treat influenza and to provide post-exposure prophylaxis. We examined the association between oseltamivir use during pregnancy and birth outcomes.

Methods

This was a nationwide registry-based prevalence study with individual level data linkage, in a setting of universal health care access. We included all recorded pregnancies in Denmark in 2002–2013, and used data from population registries to examine associations between dispensings for oseltamivir during pregnancy (first trimester, second/third trimester, none) and congenital malformations, foetal death, preterm birth, foetal growth, and low 5-min Apgar score. Adjusted odds ratios (ORs) and 95% confidence intervals (CIs) were computed using propensity score matching.

Results

The study included 946,176 pregnancies. Of these, 449 had first-trimester exposure and 1449 had second/third-trimester exposure to oseltamivir. Adjusted ORs following first-trimester exposure were 0.94 (95% CI 0.49 to 1.83) for any major congenital malformation and 1.75 (95% CI 0.51 to 5.98) for congenital heart defects, based on 7 exposed cases. The association with congenital heart defects was present for etiologically implausible exposure periods and for known safe exposures. There was no evidence of an association between prenatal exposure to oseltamivir and any of the other birth outcomes assessed.

Conclusions

The study does not provide evidence of risk associated with oseltamivir treatment additional to that associated with influenza infection.

Keywords

  • Congenital abnormalities
  • Epidemiology
  • H1N1 influenza
  • Oseltamivir

Background

Influenza infection during first trimester of gestation is associated with a 2.0-fold increased risk of any major malformation; a 3.3-fold increased risk of neural tube defects; a 1.6-fold increased risk of congenital heart defects; and with increased risks of several other types of malformations [1, 2]. Congenital heart defects are common, affecting 5–11 of 1000 live births [3], underscoring the importance of treatment and prevention of first-trimester viral infections and their sequelae. During the 2009–2010 pandemic, H1N1 influenza A infection was associated with adverse pregnancy outcomes [4, 5], while treatment with a neuraminidase inhibitor (NAI) was associated with reduced risks of admission to intensive care units and lower mortality among pregnant women [4, 6]. Oseltamivir is a NAI used in treatment and post-exposure prophylaxis of influenza [7]. Evidence about pregnancy outcomes following oseltamivir exposure is reassuring [816], including a recent study based on routine health records from four European countries reporting no evidence of an increased risk of several birth outcomes following a NAI dispensing any time during gestation [16]. Nevertheless, previous studies had limitations, which include, potential selection bias from lack of data on abortuses, and potential misclassification of the outcome, which could dilute associations.

We examined safety of prenatal exposure to oseltamivir as measured by major congenital malformations, preterm birth, reduced foetal growth, low 5-min Apgar score, or foetal death. We addressed several limitations of previous studies by including pregnancies ending in abortive outcomes and ascertaining malformations through the first birthday; using a validated algorithm for congenital heart defects; and applying advanced methods of confounding control.

Methods

Data sources

We linked data from four population-based nationwide registries in Denmark: Danish Civil Registration System [17], Danish Medical Birth Registry [18], Danish National Patient Registry [19], and Danish National Prescription Registry [20]. Additional file 1: Table S1 provides a detailed description of all data sources, including specific types of data originating from each.

Study design, population, and period

We included all pregnancies in Denmark that started and ended between 01 January 2002 and 31 December 2013. Pregnancies ending in a live birth or a stillbirth (≥22 gestational weeks) were identified in the Danish Medical Birth Registry. Pregnancies ending earlier than 22 gestational weeks in abortive outcomes were identified from hospital diagnoses recorded in the Danish National Patient Registry. Starting in 2007, the Danish National Patient Registry had information on congenital malformations identified during second-trimester therapeutic pregnancy terminations.

Exposure

The Danish National Prescription Registry provided information on dispensings for oseltamivir at outpatient (community) pharmacies. The following mutually exclusive categories of oseltamivir exposure during pregnancy were defined: exposure during the first trimester regardless of exposure in the second or third trimester; exposure during the second or the third trimester but not in the first trimester; and no exposure at any time during pregnancy (the reference category). Because organogenesis is complete in the first trimester, we examined association of first-trimester oseltamivir exposure with congenital malformations. For the remaining birth outcomes, oseltamivir exposure at any trimester was considered.

Outcomes

Congenital malformations, identified from diagnoses recorded at therapeutic second trimester abortions (2007–2013), at stillbirth, and up to 1 year postnatally in liveborn infants, were classified according to the major EUROCAT categories [3]. The Danish National Patient Registry is nearly 99% complete for diagnoses of congenital malformations [21]. For congenital heart defects, we used an algorithm developed specifically for the Danish National Patient Registry, based on the EUROCAT-specified diagnostic codes combined with therapeutic cardiac procedures [22]. The positive predictive value of this algorithm, estimated on a random sample of cases observed in this study, was 94.6% (95% confidence interval 89.2% to 97.7%). The other pregnancy outcomes were stillbirth at ≥22 weeks of gestation; foetal death (spontaneous or induced abortion before 22 weeks of gestation); preterm birth (gestational age 22- < 37 weeks) among live and stillbirths; small for gestational age (SGA) (birth weight below 10th percentile of the sex- and gestational-week-specific weight distribution) among live and stillbirths; and low 5-min Apgar score (< 7) among live births. For non-singleton pregnancies, a given outcome was considered present if recorded in at least one foetus/newborn.

Covariates

We assessed the following covariates based on their known associations with the birth outcomes: maternal age at conception, calendar year of conception, smoking as reported at the first prenatal visit (for live and stillbirths); pre-pregnancy body mass index (BMI) for live and stillbirths; mode of delivery; parity; marital status; birth of a previous child with a malformation (since 1994); indicators of maternal health care utilization (hospitalizations, visits to hospital outpatient specialist clinics, emergency room visits, dispensings for specific drug classes); maternal inpatient or outpatient morbidity (respiratory disease, cardiovascular disease, haematological disease, diabetes, neurological disease, liver or kidney disease, rheumatic disease, inflammatory bowel disease, obesity, immunodeficiency, disorders of female pelvic organs/genital tract, hospital contact for injury or poisoning); maternal outpatient dispensings for antidepressants, antiepileptics, antidiabetics, antihypertensives, drugs for ulcer/gastroesophageal reflux, oral contraceptives, drugs for in-vitro fertilization, thyroid hormones, systemic corticosteroids, non-steroidal anti-inflammatory drugs, opiates, and systemic anti-infective agents other than oseltamivir. Data on all diagnoses originated from inpatient or outpatient hospital diagnoses (secondary care), while data on medication dispensings originated from primary care and outpatient prescribing. The covariates were ascertained during 12 months preconception. Information on influenza status was not available from any data source. Definitions of the study variables appear in Additional file 1: Table S2 and Table S3.

Statistical analyses

We described the distributions of the pregnancy characteristics according to exposure to oseltamivir using appropriate descriptive statistics. For all outcomes except spontaneous or induced abortions, prevalence was used as the measure of occurrence. Crude and adjusted odds ratios (ORs) were computed using logistic regression. Pregnancies that ended before the second trimester were excluded from the analyses of second/third trimester exposure. For abortions, incidence rate was used, with hazard ratios estimated via Cox’s proportional-hazards regression, with oseltamivir exposure treated as a time-varying variable [23]. All estimates were reported with 95% confidence intervals (CIs).

Confounding was addressed using two approaches: propensity score matching and conventional adjustment using multivariate regression with generalised estimating equations to account for within-woman correlation. Propensity score matching was considered superior in control of measured confounding, while conventional adjustment allowed use of all available observations and provided the context to evaluate the direction of estimates’ change in response to tighter confounding control [24].

A propensity score for each pregnancy was computed, using logistic regression, as the probability of an oseltamivir dispensing given the covariates. Separate propensity scores were computed for the first-trimester and for the second/third-trimester exposure. Unexposed pregnancies were matched to exposed pregnancies on propensity score using nearest-neighbour matching with a caliper width of 0.2 standard deviations of the logit of the propensity score [25]. The balance of baseline characteristics was assessed post-matching, using standardised mean differences, whereby a value of ≤0.1 was considered indicative of balance. Per protocol, up to 100 oseltamivir-unexposed pregnancies were planned to be matched to each oseltamivir-exposed pregnancy. Post-matching assessment of the resulting balance indicated that only 1:1 matching achieved the target covariate balance. This 1:1 matched sample was used in propensity-score analysis, as it was deemed to remove most of the measured confounding. The covariates included in the propensity scores and the balancing statistics before and after matching are described in Additional file 1: Tables S4–S5, and Figure S1.

In conventionally adjusted analyses, we included all covariates with prevalence ≥5% or those inducing a >10% change in the crude OR. The final model included binary variables for parity (0 vs. > 0); marital status; smoking; obesity (BMI ≥30 kg/m2 or a hospital-based diagnosis of obesity); any chronic illness (cardiovascular disease, haematological disease, diabetes, neurological disease, liver or kidney disease, rheumatic disease or inflammatory bowel disease); and respiratory disease. In addition, all models included variables for mother’s age at conception (as a cubic spline) and for prior delivery of a child with a malformation. Smoking is not recorded for pregnancies ending in abortive outcomes; therefore the sensitivity analyses that contained such pregnancies were not adjusted for smoking.

The main analyses were conducted based on pregnancies ending in a live or stillbirth using propensity score to control for confounding. Since confounding by indication was expected to persist in this setting, several prespecified and post hoc sensitivity analyses were conducted for the malformation outcomes to obtain indirect evidence on confounding extent. First, we repeated the main analyses while including malformation diagnoses from terminated pregnancies (for pregnancies in 2007–2013). Second, we excluded mothers with a prior delivery of a child with a malformation. Third, we assessed risks of malformations associated with dispensing for oseltamivir during the main organogenesis period (gestational weeks 4–10 [26]). Fourth, we conducted several ‘negative control’ analyses [27]: examining effects of oseltamivir dispensing during periods etiologically implausible with respect to inducing major malformations (12 to 3 months preconception; second/third trimester of pregnancy). Fifth, we repeated the analysis replacing first-trimester exposure to oseltamivir with first-trimester exposure to penicillin, which is an anti-infective agent without evidence of teratogenicity [28] but presumed to correlate with presence of an infectious process, including fever. Finally, we examined the distribution of specific types of congenital heart defects for potential clustering, as clustering would support a causal association.

The analyses were conducted using SAS®, version 9.4 (Cary, NC, USA). Results were presented only when the individual cell counts in tables exceeded 5 observations, as specified by the Danish Data Protection Law (www.datatilsynet.dk) and/or regulations of Statistics Denmark (www.dst.dk).

Results

Between 01 January 2002 and 31 December 2013, 948,819 pregnancies started and ended in Denmark. After excluding 2643 (0.3%) pregnancies with invalid personal identifiers, 946,176 pregnancies remained in the analysis. Among these, 1898 (0.2%) pregnancies were exposed to oseltamivir: 449 during the first trimester and 1449 during the second or third trimester (Fig. 1). Of the oseltamivir-exposed pregnancies, 92% were exposed during 2009–2010. Table 1 presents characteristics of pregnancies included in the main analysis according to oseltamivir exposure, before and after propensity score matching.
Fig. 1
Fig. 1

Identification of pregnancies beginning and ending in 2002–2013, Denmark

Table 1

Characteristics of pregnancies resulting in a live or still birth, by exposure to oseltamivir

Characteristic

Before propensity score matching

After propensity score matching

Unexposed to oseltamivir during pregnancy

Exposed during first trimester

Exposed during second or third trimester

Unexposed to oseltamivir during pregnancy

Exposed during first trimester

Unexposed to oseltamivir during pregnancy

Exposed during second or third trimester

Number

670,602

406

1449

397

397

1420

1420

Age at conception (years)

  < 20

14,636 (2.2)

11 (2.7)

32 (2.2)

6 (1.5)

11 (2.8)

23 (1.6)

31 (2.2)

 20-35

549,563 (82.0)

310 (76.4)

1114 (76.9)

301 (75.8)

303 (76.3)

1109 (78.1)

1088 (76.6)

  ≥ 35

106,403 (15.9)

85 (20.9)

303 (20.9)

90 (22.7)

83 (20.9)

288 (20.3)

301 (21.2)

Age at conception (years)

 Median (IQR)

30 (26–33)

30 (27–34)

30 (27–34)

31 (27–34)

30 (27–34)

31 (27–34)

30 (27–34)

 Mean (SD)

30.0 (4.9)

30.7 (5.0)

30.8 (4.9)

31.1 (4.9)

30.8 (5.0)

31.0 (4.8)

30.8 (4.9)

Calendar year of conception

 2002-2008

426,697 (63.6)

18 (4.4)

60 (4.1)

241 (60.7)

18 (4.5)

845 (59.5)

60 (4.2)

 2009-2010

118,496 (17.7)

376 (92.6)

1335 (92.1)

78 (19.6)

367 (92.4)

265 (18.7)

1310 (92.3)

 2011-2013

125,409 (18.7)

12 (3.0)

54 (3.7)

78 (19.6)

12 (3.0)

310 (21.8)

50 (3.5)

Unmarried

357,106 (53.3)

191 (47.0)

663 (45.8)

184 (46.3)

185 (46.6)

623 (43.9)

645 (45.4)

Pre-pregnancy body mass index (kg/m2)

  < 18.5

24,336 (3.6)

20 (4.9)

46 (3.2)

6 (1.5)

20 (5.0)

55 (3.9)

46 (3.2)

 18.5- < 25.0

355,498 (53.0)

238 (58.6)

835 (57.6)

204 (51.4)

233 (58.7)

766 (53.9)

822 (57.9)

 25.0- < 30.0

118,521 (17.7)

84 (20.7)

305 (21.0)

75 (18.9)

83 (20.9)

269 (18.9)

300 (21.1)

  ≥ 30

70,259 (10.5)

54 (13.3)

212 (14.6)

48 (12.1)

52 (13.1)

166 (11.7)

206 (14.5)

 Missing

101,988 (15.2)

10 (2.5)

51 (3.5)

64 (16.1)

9 (2.3)

164 (11.5)

46 (3.2)

Smoking

 No

561,830 (83.8)

351 (86.5)

1258 (86.8)

358 (90.2)

351 (88.4)

1275 (89.8)

1258 (88.6)

 Yes

95,528 (14.2)

46 (11.3)

162 (11.2)

39 (9.8)

46 (11.6)

145 (10.2)

162 (11.4)

 Missinga

13,244 (2.0)

9 (2.2)

29 (2.0)

Parity

 0

314,229 (46.9)

136 (33.5)

441 (30.4)

122 (30.7)

132 (33.2)

415 (29.2)

427 (30.1)

 1

242,531 (36.2)

183 (45.1)

637 (44.0)

187 (47.1)

179 (45.1)

654 (46.1)

627 (44.2)

 2

86,863 (13.0)

64 (15.8)

296 (20.4)

67 (16.9)

63 (15.9)

270 (19.0)

292 (20.6)

  > 2

26,979 (4.0)

23 (5.7)

75 (5.2)

21 (5.3)

23 (5.8)

81 (5.7)

74 (5.2)

Prior delivery of a child with a malformation (since 1994)

20,171 (3.0)

16 (3.9)

67 (4.6)

19 (4.8)

16 (4.0)

72 (5.1)

64 (4.5)

Hospital history during 12 months before conceptionb

 At least one inpatient hospitalization

124,627 (18.6)

83 (20.4)

334 (23.1)

75 (18.9)

79 (19.9)

270 (19.0)

327 (23.0)

 At least one visit to outpatient specialist clinic

232,129 (34.6)

169 (41.6)

609 (42.0)

155 (39.0)

165 (41.6)

570 (40.1)

597 (42.0)

 At least one emergency room visit

85,760 (12.8)

80 (19.7)

215 (14.8)

69 (17.4)

77 (19.4)

180 (12.7)

211 (14.9)

 Respiratory diseases

33,405 (5.0)

39 (9.6)

90 (6.2)

38 (9.6)

39 (9.8)

89 (6.3)

89 (6.3)

 Cardiovascular disease

7760 (1.2)

7 (1.7)

30 (2.1)

5 (1.3)

6 (1.5)

15 (1.1)

29 (2.0)

 Haematological disease

2364 (0.4)

5 (1.2)

15 (1.0)

0 (0.0)

5 (1.3)

8 (0.6)

15 (1.1)

 Diabetes

10,590 (1.6)

5 (1.2)

38 (2.6)

7 (1.8)

5 (1.3)

29 (2.0)

37 (2.6)

 Neurological diseaseb

5654 (0.8)

5 (1.2)

20 (1.4)

 Obesityc

73,216 (10.9)

56 (13.8)

222 (15.3)

49 (12.3)

54 (13.6)

174 (12.3)

216 (15.2)

 Disorders of female pelvic organs/genital tract

44,730 (6.7)

32 (7.9)

86 (5.9)

25 (6.3)

32 (8.1)

70 (4.9)

84 (5.9)

 Hospital contact for injury or poisoning

60,037 (9.0)

51 (12.6)

148 (10.2)

51 (12.8)

50 (12.6)

130 (9.2)

144 (10.1)

Use of prescription medication in the 12 months before conception

 Antidepressants

34,293 (5.1)

30 (7.4)

115 (7.9)

29 (7.3)

29 (7.3)

105 (7.4)

109 (7.7)

 Drugs for ulcer/gastroesophageal reflux

26,456 (3.9)

27 (6.7)

84 (5.8)

18 (4.5)

26 (6.5)

80 (5.6)

83 (5.8)

 Oral contraceptives

243,936 (36.4)

156 (38.4)

534 (36.9)

173 (43.6)

153 (38.5)

517 (36.4)

523 (36.8)

 Drugs for in-vitro fertilization

54,563 (8.1)

43 (10.6)

116 (8.0)

35 (8.8)

43 (10.8)

103 (7.3)

114 (8.0)

 Thyroid hormones

7284 (1.1)

8 (2.0)

25 (1.7)

8 (2.0)

8 (2.0)

31 (2.2)

24 (1.7)

 Systemic corticosteroids

13,005 (1.9)

17 (4.2)

49 (3.4)

17 (4.3)

16 (4.0)

41 (2.9)

49 (3.5)

 Non-steroidal anti-inflammatory drugs

98,907 (14.7)

78 (19.2)

268 (18.5)

66 (16.6)

77 (19.4)

252 (17.7)

261 (18.4)

 Opiates

21,777 (3.2)

18 (4.4)

58 (4.0)

17 (4.3)

17 (4.3)

76 (5.4)

57 (4.0)

 Systemic anti-infective agents other than oseltamivir

278,680 (41.6)

195 (48.0)

734 (50.7)

189 (47.6)

190 (47.9)

740 (52.1)

719 (50.6)

Number of different drugs classes dispensed, median (IQR)

1 (1–2)

2 (1–3)

2 (1-3)

2 (1–3)

2 (1–3)

2 (1–3)

2 (1–3)

IQR interquartile range, SD standard deviation

aMatching of the unexposed pregnancies was done separately for those exposed in the first trimester and those exposed in the second or third trimester. No matching of pregnancies with missing data on smoking

bNot reported for the following protocol-specified characteristics because of low (< 5) group counts: liver and kidney disease; rheumatic disease; inflammatory bowel disease; immunodeficiency, and use of antiepileptics. In the propensity-score matched dataset neurologic diseases also not reported. cDefined by pre-pregnancy body mass index or a hospital diagnosis of obesity. Data are n (%) unless otherwise specified

Table 2 shows crude and adjusted odds ratios for the association of first-trimester exposure to oseltamivir with congenital malformations. Of the 19 first-trimester-exposed pregnancies with major congenital malformations, 8 were congenital heart defects. Among the 670,602 oseltamivir-unexposed pregnancies, prevalence of any major malformation was 3.7% and prevalence of congenital heart defects was 0.7%. Among the 406 pregnancies with first-trimester oseltamivir exposure, the prevalence of any malformation was 4.7% and the prevalence of congenital heart defects was 2.0%. The odds ratios from propensity-score matched regression analysis were 0.94 (95% CI 0.49 to 1.83) for any malformation and 1.75 (95% CI 0.51 to 5.98) for congenital heart defects. Associations for congenital heart defects were also observed in the negative control sensitivity analyses of dispensing during second or third trimester (Table 3).
Table 2

First-trimester exposure to oseltamivir and congenital malformations among live or stillbirths

Outcome

Unexposed

N = 670,602

Exposed

N = 406

Crude odds ratio (95% CI)

Adjusted odds ratio (95% CI)

Conventional regression analysisa

Propensity-score matched regression analysisb

Any major congenital malformation

24,773 (3.7%)

19 (4.7%)

1.28 (0.81 to 2.03)

1.25 (0.78 to 2.01)

0.94 (0.49 to 1.83)

Congenital heart defects

4795 (0.7%)

8 (2.0%)

2.79 (1.39 to 5.62)

2.51 (1.19 to 5.31)

1.75 (0.51 to 5.98)

CI confidence interval

aAdjusted for age at conception, parity, smoking, marital status, obesity, prior delivery of a child with a malformation, respiratory diseases, any other chronic illness (cardiovascular disease, haematological disease, diabetes, neurological disease [including antidepressants or antiepileptics use], liver or kidney disease, rheumatic disease or inflammatory bowel disease) during the 12 months before conception

bSample size: exposed = 397; unexposed = 397; prevalence of any major malformation, exposed/unexposed: 4.5%/4.8%; prevalence of congenital heart defects, exposed/unexposed: 1.8%/1.0%

Table 3

Sensitivity analyses of the outcome of congenital malformations following exposure to oseltamivir in pregnancy

 

Conventional regression analysis

Propensity-score matched regression analysis

Unexposed

Exposed

Odds ratio (95% CI) a

Unexposed

Exposed

Odds ratio (95% CI)b

Analysis including pregnancies terminated due to congenital malformations (2007-2013), prespecified

 Number

521,037

432

 

432

432

 

 Any major congenital malformation

16,692 (3.2%)

22 (5.1%)

1.58 (1.03 to 2.44)

20 (4.6%)

22 (5.1%)

1.10 (0.60 to 2.02)

 Congenital heart defects

3005 (0.6%)

8 (1.9%)

3.17 (1.57 to 6.40)

4 (0.9%)

8 (1.9%)

2.00 (0.60 to 6.64)

Pregnancies among women without an earlier pregnancy resulting in a malformed child, post hoc

 Number

650,431

390

 

381

381

 

 Any major malformation

23,712 (3.7%)

18 (4.6%)

1.26 (0.77 to 2.04)

20 (5.3%)

17 (4.5%)

0.84 (0.43 to 1.64)

 Congenital heart defects

4598 (0.7%)

8 (2.1%)

2.68 (1.27 to 5.68)

5 (1.3%)

7 (1.8%)

1.50 (0.42 to 5.32)

First trimester exposure to oseltamivir, defined as oseltamivir dispensing during 4-10 weeks of gestation, post hoc

 Number

670,602

212

 

205

205

 

 Any major malformation

24,773 (3.7%)

8 (3.8%)

0.91 (0.43 to 1.95)

8 (3.9%)

7 (3.4%)

0.88 (0.32 to 2.41)

 Congenital heart defects

4795 (0.7%)

5 (2.4%)

2.70 (1.00 to 7.29)

N/A

Oseltamivir dispensing in second or third trimester (post-organogenesis), prespecified

 Number

670,602

1449

 

1420

1420

 

 Any major malformation

24,773 (3.7%)

64 (4.4%)

1.18 (0.91 to 1.53)

51 (3.6%)

61 (4.3%)

1.21 (0.82 to 1.77)

 Congenital heart defects

4795 (0.7%)

21 (1.5%)

2.10 (1.36 to 3.24)

6 (0.4%)

21 (1.5%)

3.50 (1.41 to 8.67)

Exposure to oseltamivir between 12 and 3 months preconception, post hoc

 Number

669,934

538

 

530

530

 

 Any major malformation

24,745 (3.7%)

24 (4.5%)

1.20 (0.80 to 1.80)

19 (3.6%)

24 (4.5%)

1.28 (0.69 to 2.37)

 Congenital heart defects

N/A

First-trimester exposure to penicillin, post hocc

 Number

471,117

70,309

 

Analysis not conducted

 Any major malformation

17,148 (3.6%)

2798 (4.0%)

1.09 (1.04 to 1.13)

 Congenital heart defects

3296 (0.7%)

599 (0.9%)

1.17 (1.07 to 1.29)

CI confidence interval, N/A not applicable (counts too low to report)

aAdjusted for age at conception, parity, smoking, marital status, obesity, prior delivery of a child with a malformation, respiratory diseases, any other chronic illness (cardiovascular disease, haematological disease, diabetes, neurological disease [including use of antidepressants or antiepileptics], liver or kidney disease, rheumatic disease, or inflammatory bowel disease) during 12 months before conception

bVariables included in estimation of propensity scores are listed in the Additional file 1

cExposure to penicillin for malformations (any, congenital heart defects) among live born and stillborn infants conceived and delivered in 2002-2013 in Denmark

Table 4 presents results for the outcomes SGA, preterm birth, low 5-min Apgar score, and stillbirth. Based on propensity-score adjusted analyses, most odds ratios were close to 1.0. Some propensity-score-matched estimates were imprecise and therefore should be interpreted with caution. Table 5 shows the association between pregnancy exposure to oseltamivir and spontaneous or induced abortions, with oseltamivir as a time-varying exposure, based on 861 pregnancies exposed to oseltamivir. Adjusted incidence rate ratios associated with oseltamivir exposure were 0.99 (95% CI 0.66 to 1.48) for spontaneous abortion and 0.64 (95% CI 0.41 to 1.00) for induced abortion. No clustering of specific congenital heart defects was observed (data not shown).
Table 4

Prenatal exposure to oseltamivir and SGA, preterm birth, low 5-min Apgar score, and stillbirth

 

Unexposed

Exposed

Crude odds ratio (95% CI)

Conventional regression analysis, odds ratio (95% CI)

Propensity score-matched regression analysis, odds ratio (95% CI)c

First trimester

 Number

670,602

406

   

 Small for gestational age

64,944 (9.7%)

32 (7.9%)

0.80 (0.56 to 1.14)

0.88 (0.61 to 1.26)

0.75 (0.46 to 1.24)

 Preterm birth

42,399 (6.3%)

28 (6.9%)

1.10 (0.75 to 1.61)

1.21 (0.83 to 1.79)

0.87 (0.52 to 1.46)

 Low 5-min Apgar scorea

5429 (0.8%)

5 (1.2%)

1.52 (0.63 to 3.68)

1.64 (0.68 to 3.97)

1.00 (0.29 to 3.45)

Second/third trimester

 Number

670,602

1449

   

 Small for gestational age

64,944 (9.7%)

121 (8.3%)

0.85 (0.71 to 1.02)

0.94 (0.77 to 1.13)

0.84 (0.64 to 1.10)

 Preterm birth

42,399 (6.3%)

79 (5.4%)

0.85 (0.68 to 1.07)

0.89 (0.70 to 1.12)

0.85 (0.62 to 1.16)

 Low 5-min Apgar scorea

5429 (0.8%)

10 (0.7%)

0.85 (0.46 to 1.59)

0.92 (0.49 to 1.71)

1.25 (0.49 to 3.17)

 Stillbirthb

3047 (0.4%)

7 (0.5%)

1.06 (0.51 to 2.24)

1.13 (0.50 to 2.52)

1.20 (0.37 to 3.93)

Data are n (%) or odds ratio (95% CI) unless otherwise specified

SGA small for gestational age, CI confidence interval

aLive born only

bLive or stillborn at ≥22 weeks of gestation; data not shown for first-trimester exposure because of low counts

cVariables included in estimation of propensity scores are listed in the Additional file 1

Table 5

Exposure to oseltamivir in pregnancy and spontaneous or induced abortions

Type of abortion

Exposeda

Unexposed

Crude hazard ratio (95% CI)

Adjustedb hazard ratio (95% CI)

Spontaneous or induced

43

122

273,676

293,663

0.77 (0.57 to 1.04)

0.79 (0.59 to 1.07)

Spontaneous

24

122

104,716

293,663

1.00 (0.67 to 1.50)

0.99 (0.66 to 1.48)

Induced

19

122

168,960

293,663

0.59 (0.38 to 0.93)

0.64 (0.41 to 1.00)

CI confidence interval

aBased on 861 gestations exposed to oseltamivir

bAdjusted for age at conception, parity, smoking, marital status, obesity, prior delivery of a child with a malformation, respiratory diseases, any other chronic illness [cardiovascular disease, haematological disease, diabetes, neurological disease (including use of antidepressants or antiepileptics), liver or kidney disease, rheumatic disease or inflammatory bowel disease] during 12 months before conception

cExposure to oseltamivir is analysed as time-varying variable

Discussion

Main findings

In this population-based study, prenatal exposure to oseltamivir was not associated with increased risks of any major congenital malformation, foetal death, preterm birth, SGA or low 5-min Apgar score. For congenital heart defects, defined using a validated algorithm with high positive predictive value and completeness, exposure to oseltamivir during the first trimester was associated with an adjusted odds ratio of 1.75 (95% CI 0.51 to 5.98) based on live and stillbirths, and with an adjusted odds ratio of 2.00 (95% CI 0.60 to 6.64) after inclusion of malformations from terminated pregnancies. The association persisted for oseltamivir exposure in the second or third trimester, i.e., after completion of the organogenesis. There was no clustering of specific congenital heart defects among foetuses with first-trimester oseltamivir exposure. Because of low prevalence of oseltamivir exposure, associations with other major congenital malformations could not be evaluated.

Limitations

Important limitations of the present analysis are the low number of exposed cases and the lack of systematic data on influenza status. It is plausible to assume that during the 2009–2010 H1N1 influenza A pandemic, most oseltamivir use in pregnancy was therapeutic rather than prophylactic. This essentially guaranteed confounding by indication, especially since the unexposed pregnancies, the overwhelming majority of which were not affected by influenza, were used as the comparator in the analysis. An ideal comparator population would be composed of pregnancies affected by influenza but not treated with oseltamivir to provide the background risk of outcomes in influenza affected population. Instead, the comparator population of unexposed pregnancies represented the prevalence of congenital malformations in the general Danish population, i.e., an overall prevalence of malformations close to that reported for Denmark by the EUROCAT, based on a representative sample (2002–2012 total prevalence per 1000 births: 30 [95% CI 28 to 31] for any malformation; 9.1 [95% CI 8.4 to 10.0] for congenital heart defects [3]). The most recent analysis involving Scandinavian data [16] excluded pregnancies with a hospital-based diagnosis of influenza. This was done to reduce confounding by indication, but may have potentially introduced selection bias by excluding the most severely affected pregnancies from the study population. In our study, excluding women with a hospital diagnosis of influenza did not materially affect the findings (conventionally adjusted OR for any major congenital malformation 1.20 [95% CI: 0.74 to 1.95]).

Several considerations point to residual confounding These include increasing attenuation of odds ratios in response to closer confounding control; persisting associations for the negative control exposures, for which no association was expected unless caused by confounding – i.e., in periods after the organogenesis is expected to be complete. At the same time, the ORs for congenital heart defects were similar to those reported in other studies for first-trimester fever (1.54 [95% CI 1.37 to 1.74]) [29] or first-trimester influenza infection (1.56 [95% CI 1.13 to 2.14]) [1]. The lower precision of the odds ratios obtained in the propensity score matched analysis was the trade-off taken for maximising validity via 1:1 matching. Other limitations of this analysis are potential misclassification of exposure status by relying on dispensing records, by lack of information on oseltamivir dispensed during hospital stays, and by potential errors in recorded gestational age.

Other evidence

Taken together, the available evidence is not consistent with harmful pregnancy effects of oseltamivir or other NAIs [8, 1016]. A Canadian study of more than 55,000 pregnant women, including 1237 exposed to oseltamivir during the H1N1 pandemic, reported no evidence of an association between prenatal exposure to oseltamivir and preterm birth, low Apgar scores, or poor foetal growth [12]. Similarly, a study in Texas based on 135 oseltamivir-exposed pregnancies did not suggest harmful pregnancy effects [13]. The most recent study, conducted by Graner et al. [16], used linked databases from four European countries, including the same source data for Denmark as used in the current study and investigated similar outcomes. Graner et al. identified seven cases of congenital heart malformations in 814 first trimester oseltamivir-exposed pregnancies, resulting in a (conventionally) adjusted odds ratio of 0.96 (95% CI 0.43 to 2.15). Our study detected eight congenital heart defects in less than half as many exposed pregnancies (N = 406). This may be explained by the extension of the case detection period to up to 1 year postnatally. The differences in the conventionally adjusted odds ratios in our study compared with the study by Graner et al. (2.51 versus 0.96) may have resulted from our decision not to exclude pregnancies with hospital influenza diagnoses, combined with the higher prevalence of congenital heart defects among offspring of exposed women in our study population.

Interpretation

The OR for congenital heart defects associated with the first-trimester exposure to oseltamivir was of comparable size to that reported for influenza infection or fever, indicating that despite close control of confounding, in the setting of pregnancy, a nearly full confounding by influenza status is likely. The association was also observed during etiologically implausible periods, such as periods after completion of organogenesis; furthermore, the ORs weakened in response to successive control of measured confounding, from crude ORs (fully confounded) to conventionally adjusted ORs (some residual confounding) to propensity-score adjusted ORs (least residual confounding). Lack of clustering of specific congenital heart defects among foetuses with first-trimester oseltamivir exposure although does not disprove it, argues against the causality underlying the observed association [30]. Thus, this study in the context of the available evidence is consistent with adverse pregnancy outcomes being associated with influenza infection itself.

Conclusions

The study does not provide evidence of risk associated with oseltamivir treatment additional to that previously known to be associated with influenza infection.

Abbreviations

BMI: 

Body mass index

CI: 

Confidence interval

ICD-10: 

International Classification of Diseases, Tenth Revision

IQR: 

Interquartile range

N/A: 

Not applicable

NAI: 

Neuraminidase inhibitor

OR: 

Odds ratio

SD: 

Standard deviation

SGA: 

Small for gestational age

Declarations

Acknowledgements

We are grateful to Dr. Morten Olsen for expert advice on cardiac malformations and for conducting the case adjudication; and to the research nurses Henriette Kristoffersen and Hanne Moeslund Madsen for medical chart abstraction.

Funding

This study was funded by F. Hoffmann-La Roche Ltd. through an institutional research agreement with Aarhus University. It was designed as a Post-Authorization Safety Study in consultation with the European Medicines Agency). Employees of the funding source (BM, BC, and AK) were involved in the study design, the interpretation of data, writing of the manuscript, and the decision to submit the paper for publication. The funding source was not involved in collection or analysis of data. All authors had full access to all analysis outputs and results. The corresponding author had final responsibility for the decision to submit for publication.

Availability of data and materials

The data that support the findings of this study are available from Statistics Denmark, but restrictions apply to the availability of these data, which were used under permission exclusive to the current study, and so are not publicly available. Data access may be available by a special and reasonable request to the authors and with permission of and upon application to Statistics Denmark, and the Danish Data Protection Agency or any other agency as required by Danish law.

Authors’ contributions

VE contributed to the study design, oversaw the analyses, drafted the manuscript, and revised it critically for important intellectual content. NRK contributed to the study design, conducted the data analyses, and revised the manuscript critically for important intellectual content. BUM contributed to study design, oversaw the analyses and contributed to interpretation of results. BC provided clinical expertise, and contributed to study design. AK provided statistical expertise and contributed to the analytic strategy. HTS contributed to the study design, acquired the data, and provided clinical and epidemiologic expertise. All authors critically revised the manuscript for intellectual contents. The authors listed above approved the version to be submitted and agree to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved. All authors read and approved the final manuscript.

Ethics approval and consent to participate

The study received a required approval by the Danish Data Protection Agency [record numbers 2015-57-0002 (previously 2015-41-3838) and 2013-41-1754]. The study protocol is registered as Post-Authorisation Safety Study with the ENCePP Register of Studies, with study number EUPAS12875 (Roche identifier: BV29684). There is no requirement by Danish law to obtain informed consent or an approval by an Institutional Review Board for a registry-based study.

Consent for publication

Not applicable.

Competing interests

BM, BC and AK are full-time employees and hold stock and/or stock options in Roche, the manufacturer of oseltamivir. VE, NRK, and HTS are salaried employees of Aarhus University/Aarhus University Hospital. HTS is supported by the Program for Clinical Research Infrastructure (PROCRIN), established by the Lundbeck Foundation and the Novo Nordisk Foundation and administered by the Danish Regions. This study was funded by F. Hoffmann-La Roche Ltd. through a research agreement to and administered by Aarhus University.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Authors’ Affiliations

(1)
Department of Clinical Epidemiology, Aarhus University Hospital, Olof Palmes Allé 43-45, 8200 Aarhus N, Denmark
(2)
F. Hoffmann-La Roche Ltd., Basel, Switzerland
(3)
Roche Products Ltd., Welwyn Garden City, UK

References

  1. Luteijn JM, Brown MJ, Dolk H. Influenza and congenital anomalies: a systematic review and meta-analysis. Hum Reprod. 2014;29:809–23.View ArticleGoogle Scholar
  2. Acs N, Banhidy F, Puho E, Czeizel AE. Maternal influenza during pregnancy and risk of congenital abnormalities in offspring. Birth Defects Res A Clin Mol Teratol. 2005;73:989–96.View ArticleGoogle Scholar
  3. European Surveillance of Congenital Anomalies EUROCAT Guide 1.4, Section 3.3 EUROCAT Subgroups of Congenital Anomalies (Version 2014). 2014. http://www.eurocat-network.eu/content/EUROCAT-Guide-1.4-Section-3.3.pdf. Accessed 16 July 2017.
  4. Mosby LG, Rasmussen SA, Jamieson DJ. 2009 pandemic influenza A (H1N1) in pregnancy: a systematic review of the literature. Am J Obstet Gynecol. 2011;205:10–8.View ArticleGoogle Scholar
  5. Pierce M, Kurinczuk JJ, Spark P, Brocklehurst P, Knight M. Perinatal outcomes after maternal 2009/H1N1 infection: national cohort study. BMJ. 2011;342:d3214.View ArticleGoogle Scholar
  6. Muthuri SG, Venkatesan S, Myles PR, Leonardi-Bee J, Al Khuwaitir TS, Al Mamun A, Anovadiya AP, Azziz-Baumgartner E, Baez C, Bassetti M, et al. Effectiveness of neuraminidase inhibitors in reducing mortality in patients admitted to hospital with influenza A H1N1pdm09 virus infection: a meta-analysis of individual participant data. Lancet Respir Med. 2014;2:395–404.View ArticleGoogle Scholar
  7. McKimm-Breschkin JL. Influenza neuraminidase inhibitors: antiviral action and mechanisms of resistance. Influenza Other Respir Viruses. 2013;7(Suppl 1):25–36.View ArticleGoogle Scholar
  8. Beau AB, Hurault-Delarue C, Vial T, Montastruc JL, Damase-Michel C, Lacroix I. Safety of oseltamivir during pregnancy: a comparative study using the EFEMERIS database. BJOG. 2014;121:895–900.View ArticleGoogle Scholar
  9. Berveiller P, Mir O, Vinot C, Bonati C, Duchene P, Giraud C, Gil S, Treluyer JM. Transplacental transfer of oseltamivir and its metabolite using the human perfused placental cotyledon model. Am J Obstet Gynecol. 2012;206:92 e1–6.View ArticleGoogle Scholar
  10. Dunstan HJ, Mill AC, Stephens S, Yates LM, Thomas SH. Pregnancy outcome following maternal use of zanamivir or oseltamivir during the 2009 influenza a/H1N1 pandemic: a national prospective surveillance study. BJOG. 2014;121:901–6.View ArticleGoogle Scholar
  11. Wollenhaupt M, Chandrasekaran A, Tomianovic D. The safety of oseltamivir in pregnancy: an updated review of post-marketing data. Pharmacoepidemiol Drug Saf. 2014;23:1035–42.View ArticleGoogle Scholar
  12. Xie HY, Yasseen AS 3rd, Xie RH, Fell DB, Sprague AE, Liu N, Smith GN, Walker MC, Wen SW. Infant outcomes among pregnant women who used oseltamivir for treatment of influenza during the H1N1 epidemic. Am J Obstet Gynecol. 2013;208:293 e1–7.View ArticleGoogle Scholar
  13. Greer LG, Sheffield JS, Rogers VL, Roberts SW, McIntire DD, Wendel GD Jr. Maternal and neonatal outcomes after antepartum treatment of influenza with antiviral medications. Obstet Gynecol. 2010;115:711–6.View ArticleGoogle Scholar
  14. Donner B, Niranjan V, Hoffmann G. Safety of oseltamivir in pregnancy: a review of preclinical and clinical data. Drug Saf. 2010;33:631–42.View ArticleGoogle Scholar
  15. Saito S, Minakami H, Nakai A, Unno N, Kubo T, Yoshimura Y. Outcomes of infants exposed to oseltamivir or zanamivir in utero during pandemic (H1N1) 2009. Am J Obstet Gynecol. 2013;209:130.e1–9.View ArticleGoogle Scholar
  16. Graner S, Svensson T, Beau AB, Damase-Michel C, Engeland A, Furu K, Hviid A, Haberg SE, Molgaard-Nielsen D, Pasternak B, et al. Neuraminidase inhibitors during pregnancy and risk of adverse neonatal outcomes and congenital malformations: population based European register study. BMJ. 2017;356:j629.View ArticleGoogle Scholar
  17. Schmidt M, Pedersen L, Sorensen HT. The Danish civil registration system as a tool in epidemiology. Eur J Epidemiol. 2014;29:541–9.View ArticleGoogle Scholar
  18. Knudsen LB, Olsen J. The Danish medical birth registry. Dan Med Bull. 1998;45:320–3.PubMedGoogle Scholar
  19. Schmidt M, Schmidt SA, Sandegaard JL, Ehrenstein V, Pedersen L, Sorensen HT. The Danish National Patient Registry: a review of content, data quality, and research potential. Clin Epidemiol. 2015;7:449–90.View ArticleGoogle Scholar
  20. Kildemoes HW, Sorensen HT, Hallas J. The Danish National Prescription Registry. Scand J Public Health. 2011;39:38–41.View ArticleGoogle Scholar
  21. Larsen H, Nielsen GL, Bendsen J, Flint C, Olsen J, Sorensen HT. Predictive value and completeness of the registration of congenital abnormalities in three Danish population-based registries. Scand J Public Health. 2003;31:12–6.View ArticleGoogle Scholar
  22. Olsen M, Garne E, Svaerke C, Sondergaard L, Nissen H, Andersen HO, Hjortdal VE, Johnsen SP, Videbaek J. Cancer risk among patients with congenital heart defects: a nationwide follow-up study. Cardiol Young. 2014;24:40–6.View ArticleGoogle Scholar
  23. Savitz DA, Hertz-Picciotto I, Poole C, Olshan AF. Epidemiologic measures of the course and outcome of pregnancy. Epidemiol Rev. 2002;24:91–101.View ArticleGoogle Scholar
  24. Lawlor DA, Tilling K, Davey Smith G. Triangulation in aetiological epidemiology. Int J Epidemiol. 2016;45:1866–86.View ArticleGoogle Scholar
  25. Austin PC. A tutorial and case study in propensity score analysis: an application to estimating the effect of in-hospital smoking cessation counseling on mortality. Multivariate Behav Res. 2011;46:119–51.View ArticleGoogle Scholar
  26. Buhimschi CS, Weiner CP. Medications in pregnancy and lactation: part 1. Teratology. Obstet Gynecol. 2009;113:166–88.View ArticleGoogle Scholar
  27. Dusetzina SB, Brookhart MA, Maciejewski ML. Control outcomes and exposures for improving internal validity of nonrandomized studies. Health Serv Res. 2015;50:1432–51.View ArticleGoogle Scholar
  28. Jepsen P, Skriver MV, Floyd A, Lipworth L, Schonheyder HC, Sorensen HT. A population-based study of maternal use of amoxicillin and pregnancy outcome in Denmark. Br J Clin Pharmacol. 2003;55:216–21.View ArticleGoogle Scholar
  29. Dreier JW, Andersen AM, Berg-Beckhoff G. Systematic review and meta-analyses: fever in pregnancy and health impacts in the offspring. Pediatrics. 2014;133:e674–88.View ArticleGoogle Scholar
  30. Weiss NS. Can the “specificity” of an association be rehabilitated as a basis for supporting a causal hypothesis? Epidemiology. 2002;13:6–8.View ArticleGoogle Scholar

Copyright

© The Author(s). 2018

Advertisement